Exhibit 99.1 https://files.reportify.cc/med FOR IMMEDIATE RELEASE Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs – Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) – Jakafi (ruxolitinib) net product revenues of $741 million in Q3'24 (+16% Y/Y); raising full year 2024 Jakafi guidance to a new range of $2,740 - $2,770 million ® – Opzelura (ruxolitinib) cream net product revenues of $139 million in Q3'24 (+52% Y/Y); launch momentum cont ...